NCT06682572Phase 2Active not recruiting

A Study of Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer in Japanese Patients

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2025-12Estimated

Enrollment · participants16Actual

Source updated2025-12-17Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2025-12-17 · 3 fields changed

Participant count type changed

− Before

~~Estimated~~

+ After

Actual

Enrollment · participant count changed

− Before

~~15 participants (planned)~~

+ After

16 participants (actual)

Recruitment status changed

− Before

~~Recruiting~~

+ After

Active not recruiting

Check registry source

Study details

Conditions studied

Low Grade Serous Ovarian Cancer; Ovarian Cancer

Treatments or interventions studied

Avutometinib (VS-6766) + Defactinib (VS-6063)Drug

Primary outcomes · main study measures

Read the study measures

measure: Confirmed overall response rate (ORR; partial response [PR] + complete response [CR]; description: Confirmed overall response rate (ORR; partial response \[PR\] + complete response \[CR\] defined according to Response Evaluation Criteria in Solid Tumors version 1.1 \[RECIST v1.1\]) as assessed by the blinded independent central radiology review committee (BICR); timeFrame: From start of treatment to confirmation of response; 24 weeks

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history